Related Experiment Videos

Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure

Alberto Genovesi Ebert1, Furio Colivicchi, Marco Malvezzi Caracciolo

  • 1Cardiologia, Spedali Riuniti, Livorno, Italy. a.genovesi@tin.it

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|August 4, 2009
PubMed

Insights

Beta blockers are not recommended for Stage A heart failure prevention. However, for Stage B heart failure, especially post-myocardial infarction, beta blockers are indicated to reduce mortality and slow progression.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure prevention focuses on patients in Stages A and B of the AHA/ACC classification.
  • Stage A involves patients at risk for heart failure without structural disease, with hypertension and diabetes as key risk factors.
  • Stage B includes patients with structural heart disease but no symptoms, such as asymptomatic valvular disease or left ventricular dysfunction.

Purpose of the Study:

  • To evaluate the efficacy of beta blockers in preventing symptomatic heart failure in Stages A and B.
  • To determine the specific indications for beta blockers in different stages of heart failure prevention.

Main Methods:

  • Review of clinical trials and post hoc analyses investigating beta blocker use in heart failure prevention.
  • Analysis of data from trials like MDC, MERIT, ANZ, REVERT, SOLVD Prevention, SAVE, and CAPRICORN.

Main Results:

  • Beta blockers showed no significant advantage over other medications for preventing heart failure due to hypertension in Stage A.
  • In Stage B, particularly post-myocardial infarction (MI), beta blockers (e.g., metoprolol) improved left ventricular function and reduced mortality.
  • The REVERT trial showed metoprolol improved LV systolic volume and ejection fraction in asymptomatic patients with low ejection fraction.

Conclusions:

  • Beta blockers are not specifically indicated for Stage A heart failure prevention.
  • Beta blockers are indicated for most Stage B patients, especially post-MI, to reduce mortality and potentially prevent progression to symptomatic heart failure.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...